Health & Biotech
Osteopore specialises in the production of 3D printed bioresorbable implants that are used in conjunction with surgical procedures to assist with the natural stages of bone healing.
Osteopore is involved in designing, developing and marketing bioresorbable polymer implants for neurosurgical, orthopaedic, and maxillofacial surgery use.
Osteopore products are made of a US FDA approved polymer called polycaprolactone (PCL). PCL is bioresorbable, malleable, slow-degrading and possesses mechanical strength similar to trabecular bone.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
We’re gonna hear them roar, Osteopore deal to enter South Africa sees it with presence on every continent
Health & Biotech
Bone specialist Osteopore secures key ANZ distribution as it targets oral & maxillofacial surgery
News
Closing Bell: Sinking local markets jump ship as Central Bank prepares to board
Health & Biotech
Bone specialist Osteopore finishes solid quarter, set for new technologies and markets
News
Meet the pain: Eddy quaffed all these small cap quarterlies and we saved you the best bits
Health & Biotech
Osteopore’s star CTO gets added operations role to accelerate next-gen bone regeneration technology
Health & Biotech
Osteopore expands further into Europe after delivering maiden sale to Spain
Stockhead TV
3D Bioprinting Technology: Rapid innovations, drug discovery & printable organs
Health & Biotech
Osteopore makes first shipment to Colombia, the first of many Latin American markets it will pursue
Health & Biotech
Stock Insiders: Bone healing company Osteopore is regenerating bones with 3D-printed scaffold system
Health & Biotech
Grey matters: Osteopore shares rise on Singular opportunity to improve cranial implants through AI
Health & Biotech
ASX Health Stocks: US FDA approval could expand EBR Systems’ addressable market by $400m
News
Market Highlights and 5 ASX Small Caps to watch on Monday
Health & Biotech
Osteopore delivers strong sequential quarterly sales growth, expects further traction as pandemic restrictions loosen
Health & Biotech
Osteopore’s new Singapore deal takes a big bite out of next-gen dental implant tech
News
ASX Small Cap Lunch Wrap: Who’s overwhelmed by sheer numbers today?
Health & Biotech